Sagimet Biosciences Inc (NASDAQ: SGMT) on Tuesday, soared 5.92% from the previous trading day, before settling in for the closing price of $5.57. Within the past 52 weeks, SGMT’s price has moved between $2.13 and $20.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 43.11%. With a float of $21.13 million, this company’s outstanding shares have now reached $21.38 million.
Let’s look at the performance matrix of the company that is accounted for 10 employees. In terms of profitability, gross margin is 98.25%, operating margin of -1813.75%, and the pretax margin is -1462.55%.
Sagimet Biosciences Inc (SGMT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Sagimet Biosciences Inc is 34.36%, while institutional ownership is 53.41%. The most recent insider transaction that took place on Jul 23 ’24, was worth 74,830. In this transaction Executive Chairman of this company sold 23,625 shares at a rate of $3.17, taking the stock ownership to the 118,693 shares. Before that another transaction happened on Jul 19 ’24, when Company’s Chief Medical Officer sold 8,357 for $3.10, making the entire transaction worth $25,910. This insider now owns 81,213 shares in total.
Sagimet Biosciences Inc (SGMT) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.35 earnings per share (EPS) for the period topping the consensus outlook (set at -0.99) by 0.64. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.11% per share during the next fiscal year.
Sagimet Biosciences Inc (NASDAQ: SGMT) Trading Performance Indicators
Sagimet Biosciences Inc (SGMT) is currently performing well based on its current performance indicators. A quick ratio of 29.11 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 94.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.14, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -3.55 in one year’s time.
Technical Analysis of Sagimet Biosciences Inc (SGMT)
Sagimet Biosciences Inc (NASDAQ: SGMT) saw its 5-day average volume 1.01 million, a negative change from its year-to-date volume of 1.14 million. As of the previous 9 days, the stock’s Stochastic %D was 85.17%. Additionally, its Average True Range was 0.52.
During the past 100 days, Sagimet Biosciences Inc’s (SGMT) raw stochastic average was set at 97.50%, which indicates a significant increase from 96.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 104.92% in the past 14 days, which was lower than the 105.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.53, while its 200-day Moving Average is $4.89. Nevertheless, the first resistance level for the watch stands at $6.09 in the near term. At $6.27, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.56. If the price goes on to break the first support level at $5.62, it is likely to go to the next support level at $5.33. Assuming the price breaks the second support level, the third support level stands at $5.15.
Sagimet Biosciences Inc (NASDAQ: SGMT) Key Stats
Market capitalization of the company is 189.98 million based on 30,393K outstanding shares. Right now, sales total 2,000 K and income totals -27,880 K. The company made 0 K in profit during its latest quarter, and -8,120 K in sales during its previous quarter.
